These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 24446386)

  • 1. Interferon beta-related nephropathy and interstitial lung disease: a new association and a long-term warning.
    Capobianco M; Piccoli G; Neve Vigotti F; Scapoli P; Deagostini MC; Albera C; Roccatello D; Bertolotto A
    Mult Scler; 2014 Jun; 20(7):889-91. PubMed ID: 24446386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study.
    Frisullo G; Calabrese M; Tortorella C; Paolicelli D; Ragonese P; Annovazzi P; Radaelli M; Malucchi S; Gallo A; Tomassini V; Nociti V; D'Onghia M; Lo Re V; Rodegher M; Solaro C; Gasperini C
    Mult Scler; 2014 Aug; 20(9):1265-8. PubMed ID: 24515732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study.
    Kleinschnitz C; Niemczyk G; Rehberg-Weber K; Wernsdörfer C
    Int J Mol Sci; 2015 Jul; 16(7):15271-86. PubMed ID: 26154767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.
    Saida T; Kira J; Ueno Y; Harada N; Hirakata T
    Mult Scler Relat Disord; 2016 May; 7():102-8. PubMed ID: 27237769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
    Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP
    J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
    Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L; Guo S; Kinter E; Fay M
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between Interferon Beta-1A Administration and Intracranial Vascular Tone Regulation in Patients with Relapsing-Remitting Multiple Sclerosis: A Pilot Study.
    Dattola V; Bonanno L; Naro A; Chillura A; Logiudice AL; Sessa E; Famà F; Quartarone A; Calabrò RS; Marino S; Russo M
    Biomed Res Int; 2017; 2017():5421416. PubMed ID: 29057262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of remitting forms of multiple sclerosis].
    Lubetzki C
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):996-1000. PubMed ID: 11787366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.
    Khan O; Bao F; Shah M; Caon C; Tselis A; Bailey R; Silverman B; Zak I
    J Neurol Sci; 2012 Jan; 312(1-2):7-12. PubMed ID: 21920559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis.
    Hradilek P; Zeman D; Tudik I; Zapletalova O; Ulmann V
    Mult Scler; 2014 Apr; 20(5):639-40. PubMed ID: 23959714
    [No Abstract]   [Full Text] [Related]  

  • 13. Case report of thrombotic microangiopathy associated with subcutaneous interferon beta-1a: an emerging complication?
    Azkune Calle I; Sánchez Menoyo JL; Ruiz Ojeda J; García Moncó JC; Etxeguren Urkixo I
    Neurologia; 2016 Sep; 31(7):508-9. PubMed ID: 25449964
    [No Abstract]   [Full Text] [Related]  

  • 14. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
    Gajofatto A; Bacchetti P; Grimes B; High A; Waubant E
    Mult Scler; 2009 Jan; 15(1):50-8. PubMed ID: 18922831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
    Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
    Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis.
    Moccia M; Palladino R; Carotenuto A; Russo CV; Triassi M; Lanzillo R; Brescia Morra V
    Mult Scler Relat Disord; 2016 Nov; 10():90-96. PubMed ID: 27919507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study.
    Polman C; Barkhof F; Kappos L; Pozzilli C; Sandbrink R; Dahlke F; Jakobs P; Lorenz A;
    Mult Scler; 2003 Aug; 9(4):342-8. PubMed ID: 12926838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pearls & Oy-sters: CNS lymphoma in a patient with relapsing-remitting multiple sclerosis treated with interferon.
    Chiang S; Kesari NK; Bradshaw A; Chen W; Samudralwar R; Alobaidy AM; Kass JS
    Neurology; 2017 Oct; 89(17):e210-e213. PubMed ID: 29061682
    [No Abstract]   [Full Text] [Related]  

  • 20. Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience.
    D'Amico E; Patti F; Zanghì A; Lo Fermo S; Chisari CG; Zappia M
    Expert Rev Clin Pharmacol; 2018 May; 11(5):531-536. PubMed ID: 29521113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.